Literature DB >> 2555412

Human IL-7: a novel T cell growth factor.

P A Welch1, A E Namen, R G Goodwin, R Armitage, M D Cooper.   

Abstract

IL-7 is a hemopoietic growth factor that induces the proliferation of early B lineage cells. In the course of studies to determine its effect on human bone marrow cells, we noted a marked outgrowth of mature T cells. When T cells from the circulation were cultured with IL-7, a dose-dependent proliferative response was observed. The target cells included both the CD4+ and CD8+ subpopulations of T cells, but the memory T cells (CD45R-) were better responders than unprimed T cells (CD45R+). IL-7 induced the expression of receptors for IL-2 and transferrin and higher levels of the 4F2 activation Ag. Although T cell responses to suboptimal concentrations of IL-7 were enhanced by the addition of IL-2, the proliferative response to IL-7 was not inhibited by neutralizing antibody to the IL-2R (Tac), nor was IL-2 secretion detected in this response. This response pattern of mature T cells suggests an important role for IL-7 in normal T cell physiology in humans.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2555412

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  28 in total

1.  The serum factor from patients with ulcerative colitis that induces T cell proliferation in the mouse thymus is interleukin-7.

Authors:  M Watanabe; N Watanabe; Y Iwao; H Ogata; T Kanai; Y Ueno; M Tsuchiya; H Ishii; S Aiso; S Habu; T Hibi
Journal:  J Clin Immunol       Date:  1997-07       Impact factor: 8.317

2.  IL-7 induces clathrin-mediated endocytosis of CD127 and subsequent degradation by the proteasome in primary human CD8 T cells.

Authors:  Elliott M Faller; Feras M Ghazawi; Marko Cavar; Paul A MacPherson
Journal:  Immunol Cell Biol       Date:  2015-08-14       Impact factor: 5.126

3.  IL-7 is a potent and proviral strain-specific inducer of latent HIV-1 cellular reservoirs of infected individuals on virally suppressive HAART.

Authors:  Feng-Xiang Wang; Yan Xu; Julie Sullivan; Emily Souder; Elias G Argyris; Edward A Acheampong; Jaime Fisher; Maria Sierra; Michael M Thomson; Rafael Najera; Ian Frank; Joseph Kulkosky; Roger J Pomerantz; Giuseppe Nunnari
Journal:  J Clin Invest       Date:  2005-01       Impact factor: 14.808

4.  Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo.

Authors:  T Aoki; K Tashiro; S Miyatake; T Kinashi; T Nakano; Y Oda; H Kikuchi; T Honjo
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

5.  Comparative model building of interleukin-7 using interleukin-4 as a template: a structural hypothesis that displays atypical surface chemistry in helix D important for receptor activation.

Authors:  L Cosenza; A Rosenbach; J V White; J R Murphy; T Smith
Journal:  Protein Sci       Date:  2000-05       Impact factor: 6.725

Review 6.  The immunology of parasite infections in immunocompromised hosts.

Authors:  T Evering; L M Weiss
Journal:  Parasite Immunol       Date:  2006-11       Impact factor: 2.280

7.  Antitumor effects of interleukin-7 and adoptive immunotherapy on human colon carcinoma xenografts.

Authors:  W J Murphy; T C Back; K C Conlon; K L Komschlies; J R Ortaldo; T J Sayers; R H Wiltrout; D L Longo
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

Review 8.  Modulating T-cell homeostasis with IL-7: preclinical and clinical studies.

Authors:  C M Capitini; A A Chisti; C L Mackall
Journal:  J Intern Med       Date:  2009-08       Impact factor: 8.989

9.  Interleukin-7 is a growth factor for Sézary lymphoma cells.

Authors:  A Dalloul; L Laroche; M Bagot; M D Mossalayi; C Fourcade; D J Thacker; D E Hogge; H Merle-Béral; P Debré; C Schmitt
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

10.  Interleukin-7 (IL-7)-induced proliferation of CD8+ T-chronic lymphocytic leukemia cells.

Authors:  R Yoshioka; S Shimizu; J Tachibana; Y Hirose; M Fukutoku; Y Takeuchi; S Sugai; T Takiguchi; S Konda
Journal:  J Clin Immunol       Date:  1992-03       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.